Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
UVV Universal Corp
LNC Lincoln National Corp
FMCCG Federal Home Loan Mortgage Corp
CSAN Cosan SA
SAIC Science Applications International Corp
MUR Murphy Oil Corp
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
CODI Compass Diversified Holdings
MDRRP Medalist Diversified Reit Inc
Go


Based in Canada
Company profile

Cybin Inc. is a Canada-based biopharmaceutical company. The Company is focused on progressing psychedelic therapeutics. The Company operates business through its subsidiary Cybin Corp. The Company operates through two segments: Serenity Life Sciences Inc. (Serenity Life) and Cybin US Holdings Inc. (Cybin U.S.) that focus on the research and development of psychedelic pharmaceutical products, and Natures Journey Inc. that focuses on consumer mental wellness, including non-psychedelic nutraceutical products. The Company focuses on the development of treatment regimens consisting of psychedelic molecules and related clinical protocols. Its subsidiaries include Natures Journey Inc. (Journey), Serenity Life Sciences Inc. (Serenity), Cybin US Holdings Inc. (Cybin US), Adelia Therapeutics Inc. (Adelia) and Cybin IRL Limited.

Closing Price
$1.01
Day's Change
-0.01 (-0.98%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.09
Day's Low
1.00
Volume
(Below Average)
Volume:
741,417

10-day average volume:
923,900
741,417

Latest Earnings (Q2 ending 09/2021)

Q2
-$0.09
Q2 Consensus estimate
-$0.08

Latest Earnings Estimate Range

Highest
estimate
-$0.06
Mean
estimate
-$0.08
Lowest
estimate
-$0.11

Quarterly Consensus Estimates and Ranges

CYBN's fiscal year ends in March

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.